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Background: The low sensitivity and specificity of Plasmodium falciparum diagnostic tests pose a serious health
threat to people living in endemic areas. The objective of the study was to develop a rapid assay for the detection
of histidine-rich protein 2 (HRP2) of P. falciparum in whole blood by immunofluorescence chromatographic technology.
Methods: A total of 1163 positive and negative blood samples were screened. The double-antibody sandwich assay was
used to establish the kit and its performance was evaluated for sensitivity, specificity, accuracy, precision, stability,
and clinical effectiveness.
Results: The cut-off level of detection of the kit was 25 parasites/μl. Common interfering substances in human
blood specimens, such as bilirubin, triglyceride and cholesterol had no significant effect on HRP2 antigen detection. The
precision of the kit was run with different concentration of standard calibrators and the values were less than 10 %. The
performance of this diagnostic kit in the detection of the calibrators has shown that a shelf life of about 12 months gives
a more reliable result. Among clinical samples tested, the HRP2 test kit and the reference products had good coincidence
rate in a parallel experiment and this test kit had a more sensitive detecting level to the target protein than the reference
kits used in this study. The specificity and sensitivity for this test were 99.6 % (800/803) and 99.7 % (1160/1163),
respectively.
Conclusions: A novel HRP2 immunofluorescence detection method was developed in this study. Overall
performance evaluation indicated that the kit has a rapid, high sensitivity and on-spot method for detecting P. falciparum.
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Malaria is an infection caused by the Plasmodium parasite
that affects human health. There are over 500 million
people infected with malaria with over 1.1 million deaths
each year worldwide [1, 2]. Malaria has become a serious
public health concern in Asia, especially in countries in* Correspondence: keren_kang@hotmail.com; deek2083@yahoo.co.uk
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tention by international organizations and the developed
countries. With the boom in China’s economy and the
growing bilateral relationship with Africa and Southeast
Asia, increasing cases of malaria infection, and less effective
treatment and drug resistance have been recorded [3, 4].
Among Plasmodium infections in people, Plasmodium
falciparum is the most deadly to human beings. Plasmo-
dium falciparum at the asexual blood stage synthesizes
three kinds of histidine-rich protein (HRP): nodules-
associated HRP1, soluble HRP2 and small HRP3. Common
features of these HRP are high levels of histidine and thecle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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complete protein of the three HRPs secreted from infected
erythrocytes and serves as the most diagnostic marker re-
leased by P. falciparum [5–7].
Detection techniques of P. falciparum include morpho-
logical differentiation, molecular diagnostics and diagnostic
immunology. Morphological microscopic examination is
the gold standard for diagnosis of malaria by thick and thin
blood smears [8, 9]. It is an accurate and intuitive method
that helps to determine the infection type and quantity of
parasites present in the blood. However, thick and thin
blood examinations require professional skills and experi-
ence, demanding complex operation. Immunological diag-
nosis is an alternative method that relies on the specificity
of antigen-antibody reaction for the detection of the para-
site by applying colloidal gold method with a sensitivity of
100 parasites/μl. Polymerase chain reaction (PCR) is a more
sensitive molecular diagnostic method in which the gen-
omic deoxyribonucleic acid is extracted from infected blood
samples and P. falciparum-specific primers are used to de-
tect the presence or absence of the parasite. The sensitivity
of the PCR method can reach as high as one parasite/μl.
However, the expensive reagents, laboratory infrastructure
and skilled technical staff required for its operation makes
it unsuitable for application in point-of-care testing in
malaria-endemic areas [10–13].
In this study, the fluorescent nanoparticle labels
were applied in the double-antibody sandwich method
for the development of highly sensitive, rapid and ac-
curate P. falciparum HRP2 immunofluorescence used
in clinical diagnosis of malaria.
Methods
Reagents and instruments
Anti-PfHRP2 monoclonal antibodies and PfHRP2 recom-
binant antigen and Finecare™ Multi-channel FIA Meter
(Model Number: WF-0901/1) were provided by the Na-
tional Engineering Laboratory of Rapid Diagnostic Tests of
Guangzhou Biotech Co., Ltd, China. Fluorescent latex and
nitrocellulose membranes were purchased from Merck,
Germany. Rabbit serum immunoglobulin IgG was pur-
chased from Scantibodies, USA and Carestart™ reference
kit was from AccessBio Company, USA. Other chemical re-
agents were of analytical grade. NanoDrop 2000 C spectro-
photometer was from Thermo Fisher, USA. High-speed
refrigerated centrifuge was obtained from Hitachi, Japan.
Contact spray film machine was from Imagene Technology
Company, USA.
Sample collection
From April 2013 to July 2014, a total of 1163 (816 males
and 347 females) P. falciparum positive and negative
whole blood samples from outpatient departments were
collected at the Henan Centre for Disease Preventionand Control, Jiangsu Institute of Parasitic Diseases, and
Guangxi Centre for Disease Prevention and Control.
The mean age was 41 years (ranging between 3 and
91 years). All patients were informed of the use of their
blood samples for immunodiagnostic study and all con-
sented to participate in the study.
Plasmodium falciparum sample panel (PfSP)
This panel was prepared at the Center for Disease
Control, USA and consisted of aliquots of five cul-
tured P. falciparum parasite lines from geographically
different endemic areas. The panel was composed of
five samples each with parasite densities of 200 para-
sites/μl and 2000 parasites/μl, and two samples with
parasite density of 5000 parasites/ μl. The panel was
tested against a number of commercially available
HRP2- detecting and pLDH-detecting rapid diagnostic
tests (RDTs).
Plasmodium falciparum internal quality control panel
(PfIQCP)
The panel was provided by National Engineering
Laboratory of Rapid Diagnostic Tests of Guangzhou
Biotech Co., Ltd, China. The panel was composed of
three references with very low detection limit (L1 to L3),
one precision (J), ten negatives (N1 to N10) and positive
references (P1 to P10).
Principle
After a buffer-mixed sample is applied to the test device,
it is then inserted into Finecare™ FIA Meter and the con-
centration of the analyte is calculated by a pre-
programmed calibration process (Fig. 1). The FIA Meter
can only accept test cassette that is designed specifically
for use with this instrument. The FIA Meter is equipped
with a built-in test cassette holder and does not require
an external holder to place the cassette in. In this study,
the double-antibody sandwich assay was applied to de-
tect PfHRP2 protein in whole blood samples. The nitro-
cellulose membrane used in the preparation of the test
strip was coated with a buffer containing an anti-HRP2
monoclonal antibody. Whole blood samples were first
mixed with erythrocyte lysis buffer containing fluores-
cent, nanoparticle-labelled, anti-HRP2 monoclonal anti-
body for 30 sec to release the HRP2 protein from the
cells and to allow time for the antigen-antibody complex
formation. Then the mixed sample was added drop wise
to the sample well of the test cassette and allowed to
stand for 15 min. The reaction mixture moved along the
nitrocellulose membrane and reacted with the anti-
HRP2 antibody coated at the Test Zone (T zone) on the
nitrocellulose membranes, forming an antibody-antigen
sandwich complex. Whole blood samples containing the
HRP2 antigen accumulated more reaction complexes at
Fig. 1 FinecareTM FIA meter. The Finecare™ FIA Meter is a portable instrument for fluorescence detection of various analytes in blood or urine.
The meter equipped with a built-in test cassette holder and printer
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signal that reflected the quantity of HRP2 antigens
present in the sample. The absence of the HRP2 antigen
in the sample resulted in the absence of a detectable
fluorescent signal in the T zone. C zone is the control
zone and should have exhibited the fluorescence signal
no matter the type of antigen existing in the specimen.
Preparation of fluorescent nanoparticle-labelled
antibodies
Fluorescent latex microspheres were dissolved in phos-
phate buffer and an amount of light thio N- phthalimide
shot glass and carbodiimide were added. The mixture
placed in an ultrasonic bath at 200 W for 30 sec at room
temperature. It was incubated in the dark for 30 min
and then centrifuged. The precipitate was dissolved in
citric acid buffer. The fluorescent latex activated anti-
HRP2 monoclonal antibody was labelled as follows: 1 ml
activated latex and 0.5 mg protein were mixed thor-
oughly. The reaction mixture was then stirred at room
temperature for 2 hrs, and washed three times with
phosphate buffer by centrifugation, and the precipitate
was dissolved with a phosphate buffer solution and then
stored at 4 °C.
Preparation of working buffer
Fluorescent, nanoparticle-labelled, anti-HRP2 monoclonal
antibody and the phosphate dilution buffer were mixed in
the ratio of 1:100 and then stored at 4 °C.
Preparation of erythrocyte lysis buffer
About 8 g of ammonium chloride (0.15 M), 1 g of potas-
sium bicarbonate (10 mM), and 0.37 g of disodiumethylene diamine tetra acetic acid (1 mM) were weighed
and dissolved in 980 ml of triple-distilled water. The
resultant solution was neutralized with 1 N hydrochloric
acid or 1 N sodium hydroxide to adjust the pH: 6–6.4
and top up with triple-distilled water to a final volume
of 1000 ml. The prepared buffer was stored at room
temperature.
Preparation of test card
Coating buffer containing 1 mg/ml of HRP2 monoclonal
antibody and anti-rabbit IgG was sprayed onto a nitrocellu-
lose membrane corresponding to the T zone and C zone,
respectively. The membrane was allowed to dry overnight
at room temperature. The nitrocellulose membrane, sample
pad and absorbent paper coated with fluorescent antibody
were assembled into a test cassette and stored at 4–30 °C.
Test kit performance evaluation
The test kit performance was based on CFDA [14]. The
performance evaluation parameters include the detection
limit, sensitivity, specificity, stability, precision, clinical com-
pliance rate, and other indicators.
Cut-off values determination
About 30 HRP2 negative whole blood specimens were
thoroughly mixed with erythrocyte lysis buffer before 5 μl
of sample was added to the sample well followed by the
addition of 75 μl of buffer to test cassette and then scan-
ning with the Finecare™ Multi-channel FIA Meter. The sig-
nal ratio of the test zone to control zone (T zone/C zone)
gives the detection value of each specimen and the mean
value XBð Þ and the standard deviation (SD) of the mean
Table 1 Screening of Plasmodium falciparum control sample panel
Samples Derivation of sample Results S/CO
Benin I 200 Benin, Africa Positive 3.14
Benin I 2000 Benin, Africa Positive 9.12
Santa Lucia 200 El Salvador, Central America Positive 3.06
Santa Lucia 2000 El Salvador, Central America Positive 6.57
Nigeria XII 200 Nigeria, Africa Positive 3.52
Nigeria XII 2000 Nigeria, Africa Positive 7.76
FC27/A3 200 Papua New Guinea, Australia Positive 2.83
FC27/A3 2000 Papua New Guinea, Australia Positive 5.98
PH1 200 Philippines, Southeast Asia Positive 2.54
PH1 2000 Philippines, Southeast Asia Positive 4.72
S/CO indicates the ratio of detected value to the cut-off value. S/CO < 1 is
negative, S/CO ≧ 1 is positive. The greater the S/CO values, the higher the
HRP2 concentration
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mula XB +3SB was used as the cut-off value for the devel-
oped kit. The density of detected P. falciparum was
obtained by diluting the six positive samples of known
parasite density, sample panel with negative whole blood
and formulated as follows: 200, 100, 50, 25, 12, and 6 para-
site/μl, two batches of reagents were developed to test the
limit of detection of parasite. In the detection process, if the
detected value is greater than the cut-off value, then the
FIA Meter value is designated as ‘positive’; if it is less than
the cut-off value, then the FIA Meter value is ‘negative’.
Precision
Two batches of P. falciparum fluorescent detection kit
were compared with PfSP to test the precision of these
reference materials. Tests in each batch were repeated
ten times, and the intra-assay coefficient of variation
(CV) between batches was computed; CV < 10 % was
considered as acceptable and indicated that the test kits
were of high precision.
Interference test
Negative samples containing bilirubin (2 g/L), triglycer-
ides (3 g/L), cholesterol (15 g/L), and rheumatoid factor
(320 IU/ml), as well as positive reference samples were
tested. Test results required both positive and negative
coincidence rate at 100 % to indicate that other external
parameters do not affect the performance of reagents.
Cross-reaction trial
Cross-reaction tests were performed on other clinical sam-
ples, such as non-P. falciparum species of malaria (Plasmo-
dium ovale, Plasmodium malariae and Plasmodium vivax),
and other viral infections, including hepatitis B and C,
human immunodeficiency virus and syphilis. Ten samples
each of these clinical samples were randomly selected and
tested.
Stability test
The stability test was developed to assess the stability of
the kit. The test strips were incubated at 50 °C for one
month and the strips were tested every week using the
internal quality control panels (IQCP) to assess the sta-
bility at high temperature. The IQCP included the L1,
L1 - L3, J, N1 - N10, and P1 - P10 panels as described
earlier.
Clinical evaluation
The developed test kit was applied in the evaluation of
1163 whole blood samples obtained from the outpatient
department. Test results were compared with other
commercially available reference RDTs. Any inconsist-
ency in the results obtained was further confirmed bymicroscopic examination. The sensitivity and specificity
of this developed kit to P. falciparum and non-P. falcip-
arum species were assessed.
Statistical analysis
The positive and the negative coincidence rates of the kit
were computed as follows: positive coincidence rate (%) =
a/(a + c) × 100, and negative coincidence rate (%) = d/(b +
d) × 100; where ‘a’ is the number of positive sample in both
developed and reference tests; ‘b’ is the positive samples in
the developed test reagent, but with a negative reference
test; ‘c’ is when the developed test is negative and the refer-
ence test positive; and, ‘d’ is also negative for both tests.
Compliance rate (%) = (a + d)/(a + b + c + d) × 100.
Results
Cut-off value of the kit and the detection limit of parasite
densities
There were 30 negative whole blood specimens to be
tested and the average value was 0.45 with SD of 0.12.
With reference to technical specifications of in vitro
diagnostic kit product, the average detection value plus
three times the SD was regarded as the detection thresh-
old value, which is equal to 0.8 for this test. When the
detected value was greater than the cut-off value, the
test was designated as ‘positive’, and if it was less than
the cut-off value, the test was designated as ‘negative’.
Hence, to obtain the corresponding value of the detected
parasite density, PfIQCP with known parasite density
were serially diluted for testing. Test results showed low-
est limit of detection of about 25 parasites/μl (Table 1,
Fig. 2).
Precision result
In the assessment of the development of this diagnostic
test, precision experiment was carried out using the pre-
cision reference of PfSP to determine the positivity of
Fig. 2 Testing of negative and positive HRP 2 samples. a and b Negative HRP2 sample test. This represents the test cassette in fluorescence
excitation mode in the testing of a negative HRP2 sample (a). The absence of no target antigen in the sample is represented by the “T zone”
having no excitation peak and the “C zone” showed a fluorescence peak (b). c and d Positive HRP2 sample test. The test cassette showed band
detections at both T and C zones for positive samples (c) and the excitation in these regions are detected by the FIA and represented by the two
peaks at T and C zones
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10 % in line with the testing requirements for a good test
kit (Table 2).
Each sample was tested ten times and based on the ra-
tio of detected value to the cut-off (S/CO) value of each
test, the CV (CV = SD/mean × 100 %) within lot 1 aloneTable 2 Precision performance of the immunofluorescence test kit
Time Lot 1 Lot 2 Lot with
lot CV (%)Result S/CO Result S/CO
1 Positive 1.75 Positive 1.81 6.04
2 Positive 1.69 Positive 1.89
3 Positive 1.60 Positive 1.98
4 Positive 1.70 Positive 1.91
5 Positive 1.73 Positive 1.88
6 Positive 1.69 Positive 1.95
7 Positive 1.78 Positive 1.85
8 Positive 1.66 Positive 1.87
9 Positive 1.77 Positive 1.71
10 Positive 1.64 Positive 1.82
Within lot CV (%) 3.39 4.10
S/CO indicates the ratio of detected value to the cut-off value. S/CO < 1 is
negative, S/CO > 1 is positive. The greater the S/CO values, the higher the
HRP2 concentrationand lot 2 alone were 3.39 and 4.10 %, respectively, and
by lot with lot comparison was 6.04 % (Table 2).Interfering substances
In this study, the negative reference samples with high
concentrations of bilirubin, triglycerides, cholesterol,
and rheumatoid factor were tested and the positive and
negative coincidence rates were 100 %, which indicated
that these common contaminants did not interfere with
the test results (Table 3).Cross-reactivity
Specimens of P. vivax, P. malariae, P. ovale and other
common clinical diseases that may impact the diagnosis
of P. falciparum were tested and results showed that
both negative and positive samples did not interfere with
the diagnosis of P. falciparum (Table 4).Stability test
To ascertain the shelf life of this reagent, stability studies
were carried out on the newly developed test strips at 50 °C
for 1, 7, 15, 22, and 30 days and then tested with PfIQCP.
The results showed that the duration of storage at this high
temperature does not have any significant effect on the
minimum limit of detection, and precision detection of both
Table 3 Performance of test kit on interfering substances
Interfering
substance
Conc. Cases Negative reference samples Positive reference samples
Criterion Results Criterion Results
Bilirubin 2 g/L 20 10/10−/− 10/10−/− 10/10+/+ 10/10+/+
Triglycerides 30 g/L 20 10/10−/− 10/10−/− 10/10+/+ 10/10+/+
Cholesterol 15 g/L 20 10/10−/− 10/10−/− 10/10+/+ 10/10+/+
Rheumatoid factor 320 IU/ml 20 10/10−/− 10/10−/− 10/10+/+ 10/10+/+
10/10−/− indicates that all negative samples were tested negative for ten repeated times, and 10/10+/+ indicates that all positive samples were tested positive for
ten repeated times
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life of this test kit was estimated to be at least 12 months.
Clinical test
A total of 1163 whole blood clinical samples were tested
in multiples and parallel design. Test results were com-
pared with those obtained from reference diagnostic re-
agents. Inconsistent results were further confirmed by
the microscopic examination gold standard. The results
showed that this P. falciparum HRP2 fluorescence diag-
nostic kit had a 100 % (360/360) detection rate for posi-
tive samples whereas the Carestart colloidal gold test kit.
The specificity was 99.6 % (800/803) for the negative
samples and a sensitivity of 99.7 % (1160/1163) was ob-
served for all positive samples tested (Table 6).
Discussion
Malaria is a curable infectious disease affecting millions of
people worldwide. A rapid, sensitive and accurate diagnosis
could prevent the spread of disease in malaria-endemic
areas and guide clinical treatment for the use of anti-
malarial drugs. The immunofluorescence chromatographic
technology described here is a technique for the diagnosis
of P. falciparum HRP2.Table 4 Cross-reactivity determination
Sample type Results
Malaria samples P. malariae Negative (4/4−/−)
P. vivax Negative (10/10−/−)
P. ovale Negative (10/10−/−)
Hepatitis B virus positive
specimens
Negative (10/10−/−)









4/4−/− indicates that four cases of P. malariae specimens were tested negative;
10/10−/− indicates that ten cases corresponding cross-reactive specimens were
tested negativeHRP2 is specific to P. falciparum, which is an abun-
dant water-soluble protein with good thermal stability. It
is present in the cytoplasm of infected cells and is the
World Health Organization’s (WHO) recommended
diagnostic antigen for P. falciparum [8]. The conven-
tional PfHRP2 rapid diagnostic methods are mainly
based on labelled colloidal gold immunochromatography
and interpreted by the naked eye. The sensitivity of these
diagnostic tests is approximately 100 parasites/μl and
the low sensitivity limitations make current reagents in-
effective in the diagnosis of malaria. In order to help re-
solve this limitation, it is important to develop a novel
technique to improve the performance of the sensitivity
and specificity of RDTs.
Immunofluorescence chromatographic assay had been
used in recent years to detect the presence of HRP2 that
are in very small amounts in human blood or urine [15].
Fluorescence-based immunochromatographic assays that
employ conjugates of fluorescent microspheres and
monoclonal antibodies for detection has been reported
and suggestions of extending this technique to chemical
contaminants and antigen detection among others have
been recommended [16–18]. Similarly, a quantitative
analysis of prostate-specific antigen (PSA) in human
blood serum samples by fluorescence immunochromato-
graphy using anti-PSA monoclonal antibodies had been
demonstrated earlier [19].Table 5 Stability test and analysis












L1 L2 L3 (J) N1 to N10 P1 to P10
1 − + + 10/10+/+ 10/10−/− 10/10+/+
7 − + + 10/10+/+ 10/10−/− 10/10+/+
15 − + + 10/10+/+ 10/10−/− 10/10+/+
22 − + + 10/10+/+ 10/10−/− 10/10+/+
30 − + + 10/10+/+ 10/10−/− 10/10+/+
“+” indicates positive; “-” indicates negative
Table 6 Fluorescent HRP2 diagnostic test and reference kit in
the screening of clinical samples
Developed kit Total
Positive Negative
Reference kit Positive 360 0 360
Negative 3 800 803
Total 363 800 1,163
Compared with the reference kit, the positive coincidence rate of the two kits
is 100 %(360/360), and the negative coincidence rate is 99.62 % (800/803)
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use of the immunofluorescence chromatography for the
detection of HRP2 in malaria samples makes it an alter-
native for immunodiagnosis of the disease. This study
established a highly sensitive, rapid diagnostic reagent
based on the use of fluorescent latex particle-labelled
HRP2 antibody as a detection antibody and solid-phase
specific antibody that serves as an HRP2 capture anti-
body. The fluorescent signal was detected by a portable
FIA meter which uses an LED as the excitation light
source. The emitted light from the fluorescence dye is
collected and converted into an electrical signal and out-
puts. The signals are closely related to the amount of
fluorescein dye molecules present on the spot under
examination. In evaluating the performance of this assay,
each sample was tested ten times and based on the ratio
of detected value to the cut-off (S/CO) values, the coeffi-
cient of variation was computed both between and
within different lots.
When P. falciparum control panel was screened
against commercially available RDTs, including Wondfo
One-Step Malaria, the results showed that all samples
with 5000 parasite/μl concentrations are within the de-
tectable range of any good quality RDTs. The developed
test showed a minimum limit of detection was 25 para-
sites/μl, which is far more sensitivity than the conven-
tional immunochromatographic rapid diagnosis limit of
100 parasite/μl recommended by the WHO [20]. The re-
sults of performance evaluation for precision, stability
and cross-interference tests showed that the indicators
are in line with requirements. Interfering substances are
a major cause of errors in the clinical application of
in vitro diagnostic reagents. In this study, the negative
reference samples with high concentrations of bilirubin,
triglycerides, cholesterol, and rheumatoid factor were
tested and the positive and negative coincidence rates
were 100 %. Precision is an important measure of the
performance of in vitro diagnostic reagents within and
between batch assays. Precision assessment is an import-
ant basis for evaluating the effectiveness of the product.
In clinical trials assessing parallel multi-centre study, the
ratio of this newly developed reagent, as compared
with reference reagents, was 100 % and the negativecoincidence rate was 99.6 %. Three samples were de-
tected positive by both the newly developed fluorescent
HRP2 diagnostic test were however detected as negative
samples when the reference diagnostic test kit was used.
Further cross-examination by microscopy revealed that
there are true positive specimens with parasite density of
no more than 100 parasites/μl. This confirms the high
level of accuracy of this novel development kit and an
excellent correlation with the gold standard. It was also
observed that the test had a high precision specificity for
successfully detection of positive specimens and the pos-
sibility of producing less false negative or false positive
results as compared to other immunochromatographic
tests. Each test is estimated to cost at least one US dollar
which make it affordable for developing and low-income
countries. However, the test cannot adequately quantify
the amount of HRP2 antigen in whole blood or serum
samples. Further modifications are needed for future de-
velopment of an HRP2 quantitative-based assay. None-
theless, the very low detection limit of 25 parasites/μl
make this technique a potential alternative to low sensi-
tive RDTs in clinical settings.
Conclusions
A sensitive, rapid and accurate immunofluorescence chro-
matography assay has been developed for the detection
HRP2. The assay is an improved automated immunoassay,
less time consuming and with higher sensitivity. The quick
development of the assay is of great public health sig-
nificance for prevention and control of the epidemic of
falciparum infection and will provide important tools in
prevention and control.
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